Helen M Armstrong

Title: Helen M Armstrong: Innovator in Cannabinoid Research

Introduction

Helen M Armstrong is a notable inventor based in Westfield, NJ (US), recognized for her contributions to cannabinoid research. She holds a total of 4 patents, focusing on novel compounds that target the Cannabinoid-1 (CB1) receptor. Her work has significant implications for the treatment of various medical conditions.

Latest Patents

Among her latest patents, Armstrong has developed substituted amides and substituted pyridyoxy amides. These novel compounds serve as antagonists and/or inverse agonists of the CB1 receptor. They are useful in the treatment, prevention, and suppression of diseases mediated by the CB1 receptor. The compounds are designed to act as centrally acting drugs for conditions such as psychosis, memory deficits, cognitive disorders, migraine, neuropathy, and neuro-inflammatory disorders, including multiple sclerosis and Guillain-Barre syndrome. Additionally, they are beneficial for treating anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. Furthermore, these compounds can aid in addressing substance abuse disorders, obesity, eating disorders, asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

Career Highlights

Helen M Armstrong has worked with prominent companies in the pharmaceutical industry, including Merck & Company, Inc. and Merck Sharp & Dohme Corporation. Her experience in these organizations has contributed to her expertise in cannabinoid research and drug development.

Collaborations

Some of her notable coworkers include William K Hagmann and Linus S Lin, who have collaborated with her on various projects related to her patents.

Conclusion

Helen M Armstrong's innovative work in cannabinoid research has the potential to transform the treatment landscape for numerous medical conditions. Her contributions continue to pave the way for advancements in pharmacology and therapeutic applications.